Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch

There are limited data on the safety and efficacy of switching to secukinumab from cyclosporine A (CyA) in patients with psoriasis. The purpose of the present study was to assess the efficacy and safety of secukinumab for 16 weeks after direct switching from CyA in patients with moderate‐to‐severe p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohtsuki, Mamitaro, Morita, Akimichi, Igarashi, Atsuyuki, Imafuku, Shinichi, Tada, Yayoi, Fujita, Hiroyuki, Fujishige, Ayako, Yamaguchi, Masako, Teshima, Rie, Tani, Yumiko, Nakagawa, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655923/
https://www.ncbi.nlm.nih.gov/pubmed/28543617
http://dx.doi.org/10.1111/1346-8138.13911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655923/
https://www.ncbi.nlm.nih.gov/pubmed/28543617
http://dx.doi.org/10.1111/1346-8138.13911

Ejemplares similares